Compare · BAX vs NUWE
BAX vs NUWE
Side-by-side comparison of Baxter International Inc. (BAX) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BAX focuses on Medical/Dental Instruments, while NUWE focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- BAX is the larger of the two at $13.13B, about 7120.0x NUWE ($1.8M).
- NUWE has been more active in the news (9 items in the past 4 weeks vs 5 for BAX).
- BAX has more recent analyst coverage (25 ratings vs 1 for NUWE).
- Company
- Baxter International Inc.
- Nuwellis Inc.
- Price
- -
- -
- Market cap
- $13.13B
- $1.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 1
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest BAX
- Baxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- FDA Approval for PROPOFOL issued to BAXTER HLTHCARE CORP
- SEC Form 10-Q filed by Baxter International Inc.
- SEC Form 8-K filed by Baxter International Inc.
- Baxter Reports Third-Quarter 2026 Results
- Wolfe Research initiated coverage on Baxter
- Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
- Barclays initiated coverage on Baxter with a new price target
- New insider Rogers Terence John claimed no ownership of stock in the company (SEC Form 3)
- Baxter Releases Inaugural Connected Hospital Report
Latest NUWE
- Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
- Nuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Nuwellis Inc.
- Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
- Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
- Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
- Nuwellis to Report Third Quarter 2026 Financial Results on November 12
- Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
- SEC Form 8-K filed by Nuwellis Inc.